TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04388917

Intervention type: PROCEDURE
Intervention: Patial nephrectomy
Description: Partial nephrectomy assisted with robot to remove kidney cancer

Intervention type: PROCEDURE
Intervention: Patial nephrectomy
Description: Partial nephrectomy assisted with robot to remove kidney cancer
Study: NCT01748578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1
Description: EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1
Description: EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-1 Placebo
Study: NCT04320810

Intervention type: OTHER
Intervention: no intervention
Description: It's only observational study. No interventions.
Study: NCT03190317

Intervention type: OTHER
Intervention: HIV-infected Veterans who use MHV
Description: The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.

Intervention type: OTHER
Intervention: HIV-infected Veterans who do not use MHV
Description: The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.

Intervention type: OTHER
Intervention: Providers and staff of HIV-infected veteran
Description: The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
Study: NCT02962063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin AUC 2/paclitaxel
Study: NCT01618266

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
Study: NCT04243174

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMS Messaging
Description: Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
Study: NCT03449082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High concentration of Allo-ASC
Description: 10 million cells of Allo-ASC 0.5cc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low concentration of Allo-ASC
Description: 1 million cells of Allo-ASC 0.5cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Fibrin glue 0.5cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Fibrin glue 0.5cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrin glue
Description: Fibrin glue 0.5cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 0.5cc
Study: NCT00419926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (Myfortic)
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (Myfortic)
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Neoral)
Description: cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Neoral)
Description: cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
Study: NCT03531047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customised CXL
Description: As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
Study: NCT04320628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnaSept®
Description: AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS
Study: NCT03464812

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DSMES
Description: It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
Study: NCT02948569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-V Bioscience-2640
Description: Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
Study: NCT01204801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Microwave Thermotherapy
Description: Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (control)
Description: Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
Study: NCT02368808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abangane Support Group
Description: The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
Study: NCT01040260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Use of tangible rewards for abstinence from smoking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Nicotine patches
Study: NCT00520780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject ® (Ferric carboxymaltose)
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9%)
Description: During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
Study: NCT01189279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation A
Description: bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation B
Description: bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation C
Description: bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
Study: NCT04557072

Intervention type: DRUG
Intervention: Selective alpha-1-antagonist
Description: Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)

Intervention type: DRUG
Intervention: Non-selective alpha-1-antagonist
Description: Patients treated with non-selective alpha-blockade (phenoxybenzamine)
Study: NCT02120508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: To test the efficacy of this specific setting.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: To test the efficacy of this specific setting.
Study: NCT04434989

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT for perivascular HCC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: RFA for perivascular HCC
Study: NCT04230044

Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study: NCT03280121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophyX ZR transoral device
Description: TIF
Study: NCT02396745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Description: TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA).
Study: NCT03765866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastometry guided transfusion
Description: Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
Study: NCT01371214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLIÉ (Preventing Loss of Independence through Exercise)
Description: Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLIÉ (Preventing Loss of Independence through Exercise)
Description: Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
Study: NCT02962063

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (EBRT)
Description: Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagogastrectomy
Description: Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
Study: NCT00419926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
Study: NCT04122274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCAA education sheet
Description: A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: NCAA education sheet
Description: A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: An approximately 7-minute video that includes information about basic sports nutrition facts.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Decision-based interactive concussive education platform
Description: A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
Study: NCT02506790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study: NCT01631630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive tablet design to look exactly like pioglitazone
Study: NCT02923843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
Study: NCT01146496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraviolet light-resistant plastic in-ground pesticide storage container
Description: In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
Study: NCT03764332

Intervention type: DEVICE
Group type: OTHER
Intervention: Stabilometry
Description: To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
Study: NCT01531166

Intervention type: DRUG
Intervention: pegylated Interferon-alpha 2a
Description: Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
Study: NCT04052464

Intervention type: OTHER
Intervention: endometrium biopsy
Description: All patients will have endometrium biopsy.

Intervention type: OTHER
Intervention: endometrium biopsy
Description: All patients will have endometrium biopsy.

Intervention type: OTHER
Intervention: endometrium biopsy
Description: All patients will have endometrium biopsy.

Intervention type: OTHER
Intervention: endometrium lavage
Description: In some selected cases biopsy is preceded by endometrium lavage.

Intervention type: OTHER
Intervention: repeated endometrium lavage
Description: Endometrium lavage is repeated during the same cycle.
Study: NCT03999879

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of OxPhos upregulation
Description: OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of OxPhos upregulation
Description: OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
Study: NCT02506790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Study: NCT01538342

Intervention type: OTHER
Group type: OTHER
Intervention: 3 Biopsies
Description: 3 biopsies: 2 lesional and 1 non-lesional

Intervention type: OTHER
Group type: OTHER
Intervention: 3 Biopsies
Description: 3 biopsies: 2 lesional and 1 non-lesional
Study: NCT02571842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Rituximab
Description: - 375 mg/m2 rituximab be prescribed 4 consecutive monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI/ARB and corticosteroids
Description: * ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks
Study: NCT04121130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F-ESWT Group
Description: 3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham F-ESWT
Description: 3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
Study: NCT01225081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: oral
Study: NCT03107884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Bed Rest)
Description: A clinical oral dose of Metformin will be given to participant daily during bed rest

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Bed Rest)
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (2 week run-in only)
Description: A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2 week run-in only)
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
Study: NCT04506463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose I
Description: Intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose II
Description: Intra-articular injection
Study: NCT03999879

Intervention type: DIAGNOSTIC_TEST
Intervention: lactate (measured with 1H-MRSI)
Description: PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.

Intervention type: DIAGNOSTIC_TEST
Intervention: lactate (measured with 1H-MRSI)
Description: PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
Study: NCT02401581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter
Description: The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
Study: NCT02918110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
Study: NCT04506463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose III
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection